ClinicalTrials.gg
RecruitingNCT07886957SMART-EEGUpdated Oct 21, 2026

AI-based Algorithm Development for Improved Diagnostics in the Intensive Care and Acute Stroke Setting Using Electroencephalography

An observational study in Hemorrhagic Stroke, Intracerebral, Subarachnoid Haemorrhage (SAH) and Postanoxic Coma, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 6 months later.
Updated Oct 21, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
825
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to develop and validate artificial intelligence (AI) algorithms that use subhairline EEG (a simplified EEG patch placed on the forehead and behind the ears) to predict neurological outcome and to detect intracranial hemorrhage. The study consists of two use cases: (UC1) adults (18 years or older) in postanoxic coma after cardiac arrest who are admitted to the intensive care unit (ICU), and UC2) adults with suspected stroke or suspected subarachnoid hemorrhage (SAH) who present to the emergency department. The primary objectives are:

  • UC1: to develop and validate an AI-algorithm for outcome prediction in postanoxic coma at 24h after CA based on subhairline EEG.
  • UC2: to develop and validate an AI-algorithm for detection of ICH among patients with (suspected) stroke based on subhairline EEG and clinical symptoms.

Participants will:

  • UC1: receive a continuous subhairline EEG recording, in addition to the standard scalp EEG used in routine care. The recording starts as soon as possible after ICU admission and continues for up to 72 hours after cardiac arrest.
  • UC2: receive a single subhairline EEG recording of about 2 minutes as soon as possible after arrival. Clinical data is collected from their medical records. This includes patient characteristics, imaging, treatment and outcome at discharge. There are no follow-up visits.

In a final pilot phase, up to 10 patients per setting will be measured with the AI algorithms built into the EEG recording device, to evaluate feasibility and user-friendliness. In all phases, EEG and algorithm results are not used for clinical decisions.

Read the detailed description

**RATIONALE**

Electroencephalography (EEG) is a noninvasive tool for detecting and monitoring neuronal activity. It plays a crucial role in predicting neurological outcome in postanoxic coma after cardiac arrest (CA). It is also promising for prehospital detection of intracranial hemorrhage (ICrH), including intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH).

Conventional scalp EEG has two practical limitations. Its electrodes must be carefully placed on the scalp by specialized personnel. Its interpretation requires expertise, is time-consuming and is prone to interrater variability.

In critical care and emergency settings, time is critical and specialist availability is often limited. In acute stroke care, rapid detection of ICrH is essential to start early appropriate treatment. In postanoxic coma after CA, early EEG monitoring after ICU admission is recommended to accurately predict neurological outcome.

Recent pilot studies suggest that subhairline EEG is a reliable and easy alternative to scalp EEG for these time-critical settings. Subhairline EEG is a simplified configuration consisting of a single patch applied on the forehead and behind the ears. In addition, artificial intelligence (AI) algorithms for automated interpretation of subhairline EEG could provide rapid and reliable decision support in both settings.

**HYPOTHESIS**

The investigators hypothesize that AI algorithms based on subhairline EEG can accurately predict neurological outcome in patients with postanoxic coma after CA. The investigators also hypothesize that such algorithms can accurately detect ICH in patients with suspected stroke.

**OBJECTIVE**

  • Use case 1 (UC1): To develop and validate an AI algorithm based on subhairline EEG for outcome prediction in postanoxic coma at 24 hours after CA.
  • Use case 2 (UC2): To develop and validate an AI algorithm based on subhairline EEG and clinical symptoms for detection of ICH in patients with (suspected) stroke.

**STUDY DESIGN**

This is an investigator-initiated, monocenter, observational study at Amsterdam UMC. It consists of three steps.

Step 1: Algorithm development. Several EEG-based AI algorithms will be developed and pre-trained using existing scalp EEG data and clinical data (UC1: >900 patients, UC2: >1000 patients).

Step 2: Prospective data collection. Subhairline EEG data and clinical data will be collected with the TrianecT subhairline EEG recording device. Sample sizes are based on 10-20 events per predictor.

  • UC1: 180-360 patients
  • UC2.1 (suspected stroke): 300-600 patients
  • UC2.2 (suspected SAH): 100 patients

Step 3: Algorithm fine-tuning, validation and feasibility. The pre-trained algorithms will be fine-tuned and validated on the collected subhairline EEG data using transfer learning. The algorithms will then be integrated into the TrianecT software (SMART-EEG). Practical and clinical feasibility will be evaluated in up to 10 patients per use case. This evaluation is not intended for CE certification.

**STUDY POPULATION**

All participants are 18 years or older.

  • UC1: Patients in postanoxic coma after CA admitted to the ICU.
  • UC2.1: Patients with suspected stroke, as assessed by ambulance personnel, or with confirmed stroke.
  • UC2.2: Patients with suspected SAH, as judged by the attending paramedic, or with confirmed SAH.

**INTERVENTION**

All participants undergo a subhairline EEG recording with a single patch applied on the forehead and behind the ears.

  • UC1: continuous subhairline EEG recording, in addition to the standard scalp EEG used in routine care. The recording starts as soon as possible after ICU admission and continues up to 72 hours after CA.
  • UC2: a single subhairline EEG recording of approximately 2 minutes, performed as soon as possible after presentation at the hospital.

**MAIN END POINTS**

Primary end points:

  • UC1: the prognostic performance of subhairline EEG-based AI algorithms for prediction of neurological outcome at 24 hours after CA in postanoxic coma patients in the ICU. This is expressed as the area under the ROC curve (AUC), sensitivity, specificity and predictive values, with 95% confidence intervals. The optimal cut-off for poor outcome is defined as the highest sensitivity at a false positive rate of 0%.
  • UC2: the diagnostic accuracy of subhairline EEG-based AI algorithms for detection of ICH in (suspected) stroke patients in the emergency department. This is expressed as the AUC, and as sensitivity, specificity, PPV and NPV at the optimal cut-off, each with 95% confidence intervals.

Secondary end points:

  • Prognostic performance of AI algorithms based on subhairline EEG for outcome prediction at each hour between 6 and 24 hours after CA.
  • Diagnostic accuracy of AI algorithms based on subhairline EEG and clinical symptoms for detection of SAH.
  • Feasibility of SMART-EEG use in the ICU setting.
  • Feasibility of SMART-EEG use in the acute stroke setting, including user-friendliness as rated by users.
02

Conditions studied

  • Hemorrhagic Stroke, Intracerebral
  • Subarachnoid Haemorrhage (SAH)
  • Postanoxic Coma
03

In context

Hemorrhagic Stroke

221 studies on the registry are indexed under Hemorrhagic Stroke; 86 are open to participants now.

This study's planned enrollment of 825 is above the median of 300 across 66 observational studies indexed under Hemorrhagic Stroke.

Browse Hemorrhagic Stroke studies →

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 532 studies on the registry; 185 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (18 years or older) in three cohorts at Amsterdam UMC: patients in postanoxic coma after cardiac arrest admitted to the intensive care unit, patients with suspected or confirmed stroke presenting to the emergency department, and patients with suspected or confirmed subarachnoid hemorrhage presenting to the emergency department.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

- Age 18 years or older

Postanoxic coma (ICU):

  • Postanoxic coma after cardiac arrest, admitted to the intensive care unit
  • No objection to participation within 4 weeks of receiving an opt-out information letter

Suspected stroke (emergency department):

  • Suspected stroke as assessed by the ambulance personnel presenting the patient to the emergency department, or confirmed stroke.
  • Symptom onset, or last seen well if onset was not witnessed, less than 24 hours ago.
  • Written (deferred) informed consent by the patient or legal representative

Suspected subarachnoid hemorrhage (emergency department):

  • Suspected subarachnoid hemorrhage as judged by the attending ambulance paramedic, or confirmed subarachnoid hemorrhage.
  • Symptom onset, or last seen well if onset was not witnessed, less than 48 hours ago.
  • Written (deferred) informed consent by the patient or legal representative.

Exclusion criteria

Exclusion Criteria:

All participants:

- (Suspected) skin damage or infection at the placement area of the subhairline EEG patch

Postanoxic coma (ICU):

- Other types of severe brain injury, either pre-existing or coinciding with cardiac arrest. These include stroke, traumatic brain injury and progressive neurodegenerative disease.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
825 participants (estimated)
Patient registry
No

Groups and cohorts

  • Postanoxic coma (UC1)

    adults in postanoxic coma after cardiac arrest admitted to the ICU

  • Suspected stroke (UC2.1)

    adults with suspected or confirmed stroke presenting to the emergency department

  • Suspected SAH (UC2.2)

    adults with suspected or confirmed subarachnoid hemorrhage presenting to the emergency department

06

What researchers measure

Primary outcomes

  1. Prognostic performance of a subhairline EEG-based AI algorithm for neurological outcome prediction in postanoxic coma

    Performance of the AI algorithm, based on subhairline EEG recorded at 24 hours after cardiac arrest, in predicting poor neurological outcome. Poor outcome is defined as CPC 3-5 at hospital discharge. Performance is expressed as the area under the ROC curve (AUC), sensitivity, specificity, positive and negative predictive values, each with 95% confidence intervals. The optimal cut-off for poor outcome is defined as the highest sensitivity at a false positive rate of 0%.

    Time frame: EEG at 24 hours after cardiac arrest; neurological outcome at hospital discharge (up to 3 months after CA)

  2. Diagnostic accuracy of a subhairline EEG-based AI algorithm for detection of intracerebral hemorrhage

    Diagnostic accuracy of the AI algorithm, based on subhairline EEG and clinical symptoms, in detecting intracerebral hemorrhage (ICH) in patients with suspected stroke. The reference standard is the final diagnosis based on neuroimaging. Accuracy is expressed as the area under the ROC curve (AUC), and as sensitivity, specificity, positive and negative predictive values at the optimal cut-off, each with 95% confidence intervals.

    Time frame: EEG at presentation (within 24 hours of symptom onset); final diagnosis at hospital discharge (up to 3 months after presentation)

Secondary outcomes

  1. Prognostic performance of subhairline EEG-based AI algorithms for neurological outcome prediction at hourly intervals between 6 and 24 hours after cardiac arrest

    Performance of AI algorithms, based on subhairline EEG recorded at each hour between 6 and 24 hours after cardiac arrest, in predicting poor neurological outcome. Poor outcome is defined as CPC 3-5 at hospital discharge. Performance is expressed as AUC, sensitivity, specificity, positive and negative predictive values, each with 95% confidence intervals. The cut-off is defined as the highest sensitivity at a false positive rate of 0%.

    Time frame: EEG at each hour from 6 to 24 hours after cardiac arrest; neurological outcome at hospital discharge (up to 3 months after CA)

  2. Diagnostic accuracy of a subhairline EEG-based AI algorithm for detection of subarachnoid hemorrhage

    Diagnostic accuracy of the AI algorithm, based on subhairline EEG and clinical symptoms, in detecting subarachnoid hemorrhage (SAH) in patients with suspected SAH. Accuracy is expressed as AUC, and as sensitivity, specificity, positive and negative predictive values at the optimal cut-off, each with 95% confidence intervals.

    Time frame: EEG at presentation (within 48 hours of symptom onset); final diagnosis at hospital discharge (up to 3 months after presentation)

  3. Feasibility of SMART-EEG in the intensive care unit

    Practical and clinical feasibility of the subhairline EEG device with integrated AI algorithms (SMART-EEG) in up to 10 postanoxic coma patients in the ICU. Feasibility includes user-friendliness as rated by users . Algorithm results are not used for clinical decisions.

    Time frame: During the recording, from ICU admission up to 72 hours after cardiac arrest

  4. Feasibility of SMART-EEG in the in-hospital acute stroke setting

    Practical and clinical feasibility of SMART-EEG in up to 10 patients with suspected stroke in the emergency department. Feasibility includes user-friendliness as rated by users. Algorithm results are not used for clinical decisions.

    Time frame: At the time of the EEG recording, at presentation (Day 1)

07

Study locations

1 of 1 sites recruiting
  • Amsterdam University Medical Center
    Amsterdam, North Holland 1105 AZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available, due to privacy regulations (GDPR) and the consent procedures used in this study. Pseudonymized data may be shared with collaborating parties, including the device manufacturer, only under a data sharing agreement and only for participants who gave consent or did not object to such sharing.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 42 observational studies under Hemorrhagic Stroke, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 15. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 21, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Mar 26, 2028
CompletionEst.
Mar 26, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07886957
Responsible party
Kars Tjepkema (PhD Candidate, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Oct 21, 2026
Start date
Mar 26, 2026
Primary completion
Mar 26, 2028 (estimated)
Completion
Mar 26, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Kars Tjepkema
Contact
k.r.tjepkema@amsterdamumc.nl
0031644761222

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion